课题基金 / 基金详情

PHASE II PLACEBO CONTROLLED TRIAL OF RECOMBINANT HUMAN GM CSF

PHASE II PLACEBO CONTROLLED TRIAL OF RECOMBINANT HUMAN GM CSF
重组人类 GM CSF 的 II 期安慰剂对照试验
批准号：
6117838
负责人：
JOSEPH WHEAT
金额：
$1.7万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6117838
关键词：
HIV infections antiviral agents clinical research colony stimulating factor drug screening /evaluation health economics human morbidity human mortality human subject human therapy evaluation opportunistic infections pathologic process placebos quality of life

项目摘要

项目成果

JOSEPH WHEAT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The primary objective is to compare the incidence of opportunistic infections with GM-CSF or placebo in patients with advanced HIV infection against a background of standard antiretroviral therapy. The secondary objective is to compare the time to new or recurrent AIDS- related clinical events including opportunistic infections and malignancies; to compare survival; to compare pharmacoeconomic and quality of life parameters; to determine the occurrence of and clinical siginficance of HIV- up-regulation due to GM-CSF in a patient population receiving antiretroviral therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DAPSONE AND ATOVAQUONE FOR PROPHYLAXIS AGAINST PCP
THALIDOMIDE FOR TREATMENT OF ORAL/ESOPHAGEAL APHTHYOUS ULCERS AND HIV VIREMIA
AMBISOME VS AMPHOTERICIN B FOLLOWED BY FLUCONAZOLE IN TREATMENT OF MENINGITIS
CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA
海外基金